AVAC: Global Advocacy for HIV Prevention
AVAC: Global Advocacy for HIV Prevention was founded in December 1995 to advocate for the development of a safe, effective, and accessible HIV vaccine. It seeks to promote increased funding and investment in HIV vaccine research by government agencies, private industry and non-governmental organizations; to identify barriers to the development of a vaccine; and to increase public awareness about the need for a well funded, coordinated HIV vaccine research program. It seeks to promote increased HIV vaccine advocacy efforts by community-based organizations and increased awareness about HIV vaccine development among AIDS-affected communities. It is committed to the principle that funds for HIV vaccine research are not to be taken from basic HIV research, drug development or prevention efforts.
Latest by AVAC: Global Advocacy for HIV Prevention
A fascinating lecture at this year's HIVR4P conference showed how advances in modern scanning technologies can be used to get more accurate information about the first stages of HIV infection and on the ways that HIV drugs are absorbed and distribute...
Research on broadly neutralizing antibodies is taking the field of HIV prevention science in new directions, with implications for new prevention interventions and vaccine development.
Rob Newells, executive director of the AIDS Project of the East Bay, gives his personal (U.S.-centered, black MSM-focused) highlights from CROI 2018.
This year's Conference on Retroviruses and Opportunistic Infections broadened its lens from the lab to the ways that different strategies are, or might, have an impact in the context of people's complex lives.
"There is good news and bad news, often in the same story," AVAC writes.
A new report documents 2016 funding and highlights a continuing trend of flat or declining funding and its potential impact on further innovation in HIV prevention research and development.
A medicine you get only every two months to reduce your risk of acquiring HIV could be an option in the future, but only if two clinical trials show that it is safe and effective.
"Good participatory practice and community voices are needed now more than ever in the HIV vaccine research arena," Daisy Ouya and Morenike Upkong write.
A medicine that can be administered once every two months to reduce HIV risk could be an option in the future if two big efficacy trials find good results.
"At CROI, the 'executive director hat' comes off, and I'm purely a community advocate again," Rob Newells writes. "This year, that was even more true than in previous years."